CooperVision completes MiSight study enrollment

CooperVision has finished enrolling children into its global MiSight 1 day post-approval studies in the United States and China, according to a company announcement dated May 18. The program is aimed at generating real-world evidence for pediatric myopia control after the product’s regulatory approvals, rather than adding another tightly controlled pre-approval efficacy trial. (coopervision.com) The company said the combined studies cover more than 100 clinical sites and include over 3,000 children. (coopervision.com) CooperVision said the work will add to the published clinical record for MiSight 1 day and provide data from routine practice settings across two large pediatric populations. (clinicaltrials.gov) ### Why is CooperVision still studying MiSight after approval? MiSight 1 day is already a marketed product, but post-approval studies are meant to track how a therapy performs outside idealized trial conditions. CooperVision said the U.S. and China programs are designed to produce real-world evidence for pediatric myopia management and to supplement earlier randomized and registry data. (coopervision.com) Jennifer Palombi, CooperVision’s director of professional affairs for the Americas, said in the company release that clinicians want “long-term, real-world data” that reflects how myopia control is actually practiced. Her statement framed the enrollment milestone as part of evidence-building for eyecare professionals managing children over multiple years. (coopervision.com) ### What does “real-world evidence” mean here? The U.S. ClinicalTrials.gov listing says the post-approval study is intended to confirm the effectiveness of MiSight 1 Day in clinical practices within the United States and to assess the stability of myopia reduction over one year after treatment ends. (coopervision.com) The registry describes a multicenter, randomized, controlled, double-masked study lasting four years, with a three-year treatment phase followed by a one-year post-treatment period. That design matters because post-approval evidence often answers a different question from pivotal trials: not only whether a product can work under protocol conditions, but whether outcomes hold up in broader clinical use. In this case, the company is explicitly tying the next phase of evidence to everyday pediatric practice. (coopervision.com) ### How large is the program? CooperVision said the U.S. and China studies together make up what it called the longest international clinical evidence program yet undertaken for soft contact lens-based myopia control in children. The company said the evidence package includes randomized controlled efficacy trials as well as large-scale safety registries. (clinicaltrials.gov) The Canadian version of the company release added that, together with the seven-year clinical trial of ActivControl Technology, the studies form the longest and most comprehensive clinical evidence program the company has assembled for contact lens-based myopia control in children. That wording is the company’s characterization, but it shows how CooperVision is positioning MiSight within a longer evidence arc rather than as a single trial result. (coopervision.com) ### Why were the United States and China chosen? Participants in the multi-year studies come from populations across the United States and China, CooperVision said, and the company said that breadth should produce findings with wider relevance. (coopervision.com) The company did not, in the materials reviewed, break out enrollment by country or site. The two-country setup gives CooperVision access to large pediatric populations and different care environments, which is consistent with the company’s stated goal of gathering evidence that reflects routine practice. That is an inference from the study geography and the company’s description of the program as real-world evidence generation. (coopervision.ca) ### What comes next? CooperVision said final data from the post-approval studies is expected on a rolling basis between 2027 and 2030. The company also said it has released a report titled “Progress in Focus: The Global Impact of MiSight 1 day,” which it described as a summary of the product’s broader evidence base. (coopervision.com)